PE20021159A1 - Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo - Google Patents

Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo

Info

Publication number
PE20021159A1
PE20021159A1 PE2002000369A PE2002000369A PE20021159A1 PE 20021159 A1 PE20021159 A1 PE 20021159A1 PE 2002000369 A PE2002000369 A PE 2002000369A PE 2002000369 A PE2002000369 A PE 2002000369A PE 20021159 A1 PE20021159 A1 PE 20021159A1
Authority
PE
Peru
Prior art keywords
nelfinavir
dosage form
fusion
pharmaceutical dosage
amorphous
Prior art date
Application number
PE2002000369A
Other languages
English (en)
Inventor
Martin Howard Infeld
Wantanee Phuapradit
Lin Zhang
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20021159A1 publication Critical patent/PE20021159A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A UNA FORMA DE DOSIFICACION FARMACEUTICA ORAL SOLIDA QUE COMPRENDE MESILATO DE NELFINAVIR AMORFO UTILIZANDO DE 400mg A 700mg Y UN COPOLIMERO DE BLOQUEO DE OXIDO DE ETILENO Y OXIDO DE PROPILENO, SINTETICO, NO IONICO, SOLUBLE EN AGUA, PUNTO DE FUSION DE 40°C, VALOR DE HLB A 25°C DE 14 A 29; EXCIPIENTES TAL COMO ESTABILIZANTES, AGENTES HUMECTANTES, AGLUTINANTES, DISGREGANTES, DILUYENTES, SOLUBILIZANTES, LUBRICANTES. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE CALENTAR UNA MEZCLA DE MESILATO DE NELFINAVIR AMORFO Y EL POLIMERO DE BLOQUEO DE OXIDO DE ETILENO Y OXIDO DE PROPILENO SINTETICO NO IONICO, SOLUBLE EN AGUA; MEZCLAR LA AMALGAMA PARA FORMAR UN GRANULADO DE FUSION; PROCESAR EL GRANULADO DE FUSION EN DICHA FORMA DE DOSIFICACION DE MESILATO DE NELFINAVIR AMORFO. EL COPOLIMERO PROPORCIONA A LA FORMULACION DE NELFINAVIR MEJOR DISOLUCION Y BIODISPONIBILIDAD
PE2002000369A 2001-05-03 2002-04-30 Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo PE20021159A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28841001P 2001-05-03 2001-05-03

Publications (1)

Publication Number Publication Date
PE20021159A1 true PE20021159A1 (es) 2002-12-20

Family

ID=23106974

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000369A PE20021159A1 (es) 2001-05-03 2002-04-30 Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo

Country Status (37)

Country Link
US (1) US7014866B2 (es)
EP (1) EP1390063B1 (es)
JP (1) JP4101661B2 (es)
KR (1) KR100554816B1 (es)
CN (1) CN1255185C (es)
AR (1) AR034320A1 (es)
AT (1) ATE282428T1 (es)
BG (1) BG108311A (es)
BR (1) BR0209325A (es)
CA (1) CA2444116C (es)
CZ (1) CZ20033211A3 (es)
DE (1) DE60201988T2 (es)
EA (1) EA006627B1 (es)
EC (1) ECSP034827A (es)
ES (1) ES2231717T3 (es)
GE (1) GEP20053466B (es)
GT (1) GT200200079A (es)
HK (1) HK1070285A1 (es)
HR (1) HRP20030873B1 (es)
HU (1) HU229938B1 (es)
IL (2) IL158306A0 (es)
IS (1) IS7010A (es)
JO (1) JO2401B1 (es)
MA (1) MA27018A1 (es)
MX (1) MXPA03009971A (es)
MY (1) MY128509A (es)
NO (1) NO20034689D0 (es)
NZ (1) NZ528689A (es)
PA (1) PA8544501A1 (es)
PE (1) PE20021159A1 (es)
PL (1) PL366998A1 (es)
PT (1) PT1390063E (es)
RS (1) RS83503A (es)
SK (1) SK14572003A3 (es)
TW (1) TWI234461B (es)
UA (1) UA76463C2 (es)
WO (1) WO2002089835A2 (es)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2398226A1 (en) * 2002-01-28 2003-07-28 Pfizer Inc. Increased-dosage nelfinavir tablet and method of making same
WO2005004868A1 (ja) * 2003-07-15 2005-01-20 Arigen, Inc. 抗コロナウイルス剤
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0418330A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas de drogas de solubilidade baixa e poloxámeros
CA2588445C (en) * 2004-12-03 2013-06-25 Merck & Co., Inc. Pharmaceutical formulation containing a release rate controlling composition
DK1928427T3 (da) * 2005-09-23 2010-03-08 Hoffmann La Roche Hidtil ukendt dosisformulering
CN101330906B (zh) * 2005-12-14 2010-12-29 弗·哈夫曼-拉罗切有限公司 Hcv前药制剂
WO2007068615A2 (en) * 2005-12-14 2007-06-21 F. Hoffmann-La Roche Ag Hcv prodrug formulation
BRPI0714265A2 (pt) * 2006-08-10 2013-04-16 Cipla Ltd composiÇço oral sàlida, processo para preparar uma composiÇço oral sàlida, uso de uma composiÇço e mÉtodo para tratar hiv
CN101516339B (zh) * 2006-08-16 2012-06-13 诺瓦提斯公司 制备高度结晶的治疗化合物的固体分散体的方法
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
US8759383B2 (en) 2007-03-16 2014-06-24 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
US7528131B2 (en) * 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
EP2152689B1 (en) 2007-04-25 2013-01-02 Concert Pharmaceuticals Inc. Analogues of cilostazol
US9194512B2 (en) 2007-04-30 2015-11-24 Mark Andreychuk Coiled tubing with heat resistant conduit
US8567657B2 (en) * 2007-04-30 2013-10-29 Mtj Consulting Services Inc. Coiled tubing with retainer for conduit
AU2008247805A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
EP4183787A1 (en) 2007-05-01 2023-05-24 Concert Pharmaceuticals Inc. Morphinan compounds
PT2792662T (pt) 2007-05-01 2016-07-07 Concert Pharmaceuticals Inc Compostos de morfinano
WO2008137474A1 (en) 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Morphinan compounds
AU2008267048C1 (en) 2007-06-12 2013-01-17 Concert Pharmaceuticals, Inc. Azapeptide derivatives
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
EP2214635A1 (en) * 2007-10-19 2010-08-11 Purdue Research Foundation Solid formulations of crystalline compounds
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
JP5567503B2 (ja) 2008-02-29 2014-08-06 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
US20100221221A1 (en) * 2008-08-12 2010-09-02 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
PL3248978T3 (pl) 2008-09-19 2019-12-31 Concert Pharmaceuticals Inc. Zdeuterowane związki morfinanu
EP3090760A1 (en) 2008-10-30 2016-11-09 Concert Pharmaceuticals, Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
EP2397159A3 (en) 2008-10-30 2012-02-22 Concert Pharmaceuticals, Inc. Combination of morphinan compounds and antidepressant for the treatment of intractable and chronic pain
WO2010053550A2 (en) 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
AP2909A (en) 2009-03-17 2014-05-31 Concert Pharmaceuticals Inc Pyrazinoisoquinoline Compounds
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
WO2011005520A1 (en) 2009-06-23 2011-01-13 Concert Pharmaceuticals, Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
WO2011103457A1 (en) 2010-02-18 2011-08-25 Concert Pharmaceuticals Inc. Pyrimidine derivatives
EP2566494B1 (en) 2010-02-26 2017-11-29 Acer Therapeutics, Inc. Cxcr4 receptor compounds
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2011109464A1 (en) 2010-03-02 2011-09-09 Concert Pharmaceuticals Inc. Deuterated tetrahydronaphthalene derivatives
CA2800442C (en) * 2010-06-14 2018-05-22 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition with modified release
WO2012037060A1 (en) 2010-09-13 2012-03-22 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
JP2014506603A (ja) 2011-02-25 2014-03-17 コンサート ファーマシューティカルズ インコーポレイテッド ２−アミノ−ナフチリジン誘導体
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012154728A1 (en) 2011-05-10 2012-11-15 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
MX349159B (es) 2011-05-18 2017-07-14 Concert Pharmaceuticals Inc Derivados deuterados de ivacaftor.
US20140296263A1 (en) 2011-07-19 2014-10-02 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
FR2985177B1 (fr) * 2012-01-02 2016-04-01 Oreal Composition cosmetique solide aqueuse comprenant de l'alkylcellulose, au moins deux huiles non volatiles et au moins deux agents tensioactifs
EP2802596A1 (en) 2012-01-09 2014-11-19 Anchor Therapeutics, Inc. Apj receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CN104364255A (zh) 2012-04-13 2015-02-18 康塞特医药品有限公司 取代的黄嘌呤衍生物
EP2838879A1 (en) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Deuterated rigosertib
CA2876306C (en) 2012-06-15 2024-02-20 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
WO2014012009A1 (en) 2012-07-12 2014-01-16 Concert Pharmaceuticals, Inc. Deuterated idebenone
AU2013302519B2 (en) 2012-08-17 2017-11-02 Concert Pharmaceuticals, Inc. Deuterated baricitinib
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
JP2016503798A (ja) 2012-12-20 2016-02-08 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化ａｌｋ阻害剤
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CA2906396A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
CA2904054A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals, Inc. Deuterated palbociclib
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
EP3021861A1 (en) 2013-07-18 2016-05-25 Anchor Therapeutics, Inc. Apj receptor compounds
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
EP3105232B1 (en) 2014-02-10 2019-08-28 Concert Pharmaceuticals Inc. Substituted triazolobenzodiazepines
CN106456647A (zh) 2014-04-18 2017-02-22 康塞特医药品有限公司 治疗高血糖症的方法
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
CN106459004B (zh) 2014-06-06 2020-09-15 研究三角协会 爱帕琳肽受体(apj)激动剂及其用途
EP3808349B1 (en) 2014-08-07 2022-10-05 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016094011A1 (en) * 2014-12-11 2016-06-16 Merck Sharp & Dohme Corp. Crystal forms of a ccr5 antagonist
CN105769809A (zh) * 2014-12-23 2016-07-20 上海星泰医药科技有限公司 提高生物利用度的雷尼司他及其制备方法
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
EP3265440A1 (en) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Deuterated emricasan
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
WO2017020002A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
CN108367002A (zh) 2015-09-21 2018-08-03 弗特克斯药品欧洲有限公司 氘化cftr增强剂的给予
US11267777B2 (en) 2015-11-19 2022-03-08 Concert Pharmaceuticals, Inc. Deuterated EPI-743
AU2016366310C1 (en) 2015-12-09 2021-09-09 Research Triangle Institute Improved apelin receptor (APJ) agonists and uses thereof
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
AU2017261286B2 (en) 2016-05-04 2023-03-23 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
ES2840078T3 (es) 2016-07-04 2021-07-06 Avanir Pharmaceuticals Inc Métodos para la síntesis de dextrometorfano deuterado
US11596605B2 (en) 2016-08-01 2023-03-07 The Brigham And Women's Hospital, Inc. Particles for delivery of proteins and peptides
WO2018160717A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
MX2019013769A (es) 2017-05-19 2020-07-20 Superb Wisdom Ltd Derivados de resiquimod.
CN111491629A (zh) 2017-11-22 2020-08-04 康塞特医药品公司 D-丝氨酸的氘化类似物及其用途
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US20230390292A1 (en) 2020-10-28 2023-12-07 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
AU2022328272A1 (en) 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CA3228509A1 (en) 2021-08-12 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6001851A (en) 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
PT998271E (pt) * 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
AU9496798A (en) * 1997-09-19 1999-04-05 Shire Laboratories, Inc. Solid solution beadlet
EP1227797B1 (en) * 1999-11-12 2005-01-12 Abbott Laboratories Solid dispersion pharmaceutical formulations
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation

Also Published As

Publication number Publication date
EP1390063A2 (en) 2004-02-25
GT200200079A (es) 2002-12-05
TWI234461B (en) 2005-06-21
CA2444116A1 (en) 2002-11-14
UA76463C2 (en) 2006-08-15
JP4101661B2 (ja) 2008-06-18
HUP0401238A3 (en) 2012-09-28
AR034320A1 (es) 2004-02-18
EA200301166A1 (ru) 2004-04-29
JP2004527569A (ja) 2004-09-09
JO2401B1 (en) 2007-06-17
HU229938B1 (en) 2015-01-28
BR0209325A (pt) 2004-07-20
MXPA03009971A (es) 2004-02-12
CA2444116C (en) 2009-01-20
NO20034689L (no) 2003-10-20
GEP20053466B (en) 2005-02-25
ATE282428T1 (de) 2004-12-15
US7014866B2 (en) 2006-03-21
HRP20030873A2 (en) 2005-08-31
IL158306A (en) 2008-11-03
EA006627B1 (ru) 2006-02-24
US20030021840A1 (en) 2003-01-30
IS7010A (is) 2003-10-30
WO2002089835A3 (en) 2003-05-01
ECSP034827A (es) 2003-12-24
CN1255185C (zh) 2006-05-10
HUP0401238A2 (hu) 2004-12-28
CN1547484A (zh) 2004-11-17
PA8544501A1 (es) 2002-11-18
NZ528689A (en) 2005-03-24
SK14572003A3 (sk) 2004-12-01
HK1070285A1 (en) 2005-06-17
BG108311A (bg) 2004-12-30
HRP20030873B1 (en) 2006-04-30
ES2231717T3 (es) 2005-05-16
PT1390063E (pt) 2005-03-31
KR20040007523A (ko) 2004-01-24
CZ20033211A3 (cs) 2004-09-15
EP1390063B1 (en) 2004-11-17
PL366998A1 (en) 2005-02-07
IL158306A0 (en) 2004-05-12
DE60201988T2 (de) 2005-12-15
RS83503A (en) 2006-10-27
WO2002089835A2 (en) 2002-11-14
KR100554816B1 (ko) 2006-02-22
DE60201988D1 (de) 2004-12-23
MA27018A1 (fr) 2004-12-20
MY128509A (en) 2007-02-28
NO20034689D0 (no) 2003-10-20

Similar Documents

Publication Publication Date Title
PE20021159A1 (es) Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo
PL1689724T3 (pl) Związki chinazolinonowe jako leki przeciwnowotworowe
ES2171884T3 (es) Compuestos de quinazolina.
AR018143A1 (es) Formulacion para preparar un comprimido de desintegracion rapida, comprimidos de desintegracion rapida, especialmente comprimidos de desintegracionrapida en la boca
EP1467970A4 (en) HYDROXYNAPHTHYRIDINONCARBOXYL ACID AMIDES SUFFICIENT AS INHIBITORS OF THE HIV INTEGRASE
AR077411A2 (es) Forma de dosificacion farmaceutica solida, con lopinavir y ritonavir, y proceso para su preparacion.
ECSP066512A (es) Formulación y método de aripiprazol inyectable estéril de liberación controlada
DE602004025698D1 (de) PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS
CL2007001090A1 (es) Compuestos derivados de diazepano, antagonistas de los receptores ccr-2, ccr-5 y ccr-3; procedimiento de preparacion; composicion farmaceutica; compuesto intermediario; y uso del compuesto en el tratamiento de una enfermedad oclusiva de arterias perifericas, isquemia critica de extremidades, angina inestable, apoplejia, entre otras
UY27374A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales
IL154988A0 (en) Pharmaceutical compositions containing a 5-ht3 receptor antagonist
ECSP088239A (es) Composición de liberación de fármaco sostenida
AR103653A1 (es) Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen
TW200628466A (en) Quinazoline derivatives
DE60323743D1 (en) N-(substituierte benzyl)-8-hydroxy-1,6-naphthyridin-7- carbonsäureamide als hiv-integrase-hemmer
MY197663A (en) Pharmaceutical formulation
AR077884A1 (es) (4-(5-aminometil- fenil)-piperidin-1-il)-1h-indol-3-il)-metanonas disustituidas
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
ES2150404T1 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
EE04966B1 (et) (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks
SE0000303D0 (sv) Novel compounds
AR044450A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
CO5170463A1 (es) Formas polimorfas de un citrato de azobiciclo [2,2,2]octan- 3-amina y sus composiciones farmaceuticas
CO5170468A1 (es) Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas
AR028470A1 (es) Ariltiofeno agonistas de vasopresina, el uso de los mismos para manufactura de un medicamento y composicion farmaceutica

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed